Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Anthony De Soyza (Newcastle upon Tyne, United Kingdom), Anthony De Soyza, Timothy Aksamit, Elisabeth Operschall, Tiemo-Joerg Bandel, Ulrike Krahn, Margarita Criollo, Robert Wilson. LATE-BREAKING ABSTRACT: Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB). Eur Respir J 2015; 46: Suppl. 59, 2617

Member's Comments

No comment yet.

Related content which might interest you: Baseline profiles of subjects randomised in RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-CF bronchiectasis (NCFB) by pathogen and prior exacerbation rate Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 LATE-BREAKING ABSTRACT: RESPIRE 1: Ciprofloxacin DPI 32.5mg b.d. administered 14 day on/off or 28 day on/off vs placebo for 48 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFB) Source: International Congress 2016 – Clinical update on bronchiectasis Year: 2016 Influence of severity on outcome in a phase II trial of ciprofloxacin DPI in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013 LATE-BREAKING ABSTRACT: Inhaled mannitol for non-cystic fibrosis bronchiectasis: results of a 12 month, multi-centre, double-blind, controlled study. Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017 Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018 Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013 A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 LATE-BREAKING ABSTRACT: Two Phase 3 placebo-controlled trials of Aztreonam Lysine for Inhalation (AZLI) for Non-Cystic Fibrosis Bronchiectasis (NCFB) Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE) Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011 Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016 Longitudinal performance of the bronchiectasis severity index (BSI) in patients on regular intravenous (IV) antibiotic therapy for bronchiectasis Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study Source: Eur Respir J 2013; 41: 1107-1115 Year: 2013 Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis Source: Eur Respir J, 51 (1) 1702052; 10.1183/13993003.02052-2017 Year: 2018 Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015 RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis Source: Eur Respir J, 51 (1) 1702053; 10.1183/13993003.02053-2017 Year: 2018 Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA). Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 A randomised placebo-controlled dose finding study of tobramycin inhalation powder (TIP) in patients with bronchiectasis (BE) and pulmonary P. aeruginosa Pa) infection (iBEST-1) Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018